Background Background Despite several
Despite several treatmentoptions, adherence totherapyis treatmentoptions, adherence totherapyis poor in patients with bipolar disorder. poor in patients with bipolar disorder.
Aims Aims A double-blind, controlled
A double-blind, controlled comparison of aripiprazole and comparison of aripiprazole and haloperidol in patients with bipolar I haloperidol in patients with bipolar I disorder experiencing acute manic or disorder experiencing acute manic or mixed episodes. mixed episodes.
Method Method Patients (
Patients (n n¼347) were 347) were randomised to receive aripiprazole or randomised to receive aripiprazole or haloperidol in this12-week, multicentre haloperidol in this12-week, multicentre study.The primary outcome measure was study.The primary outcome measure was the number of patients in response the number of patients in response ( (5 550% improvement from baseline in 50% improvement from baseline in Young Mania Rating Scale score) and Young Mania Rating Scale score) and receiving therapy at week12. receiving therapy at week12.
Results
Results At week12, significantly more At week12, significantly more patients taking aripiprazole (49.7%) were patients taking aripiprazole (49.7%) were in response and receiving therapy in response and receiving therapy compared with those taking haloperidol compared with those taking haloperidol (28.4%; (28.4%; P P5 50.001).Continuation rates 0.001).Continuation rates differed markedly between treatments differed markedly between treatments (week12: aripiprazole, 50.9%; (week12: aripiprazole, 50.9%; haloperidol, 29.1%).Extrapyramidal haloperidol, 29.1%).Extrapyramidal adverse events were more frequent with adverse events were more frequent with haloperidol than aripiprazole (62.7% haloperidol than aripiprazole (62.7% v.
v. 24.0%). 24.0%).
Conclusions Conclusions Aripiprazole showed
Aripiprazole showed superior levels of response and tolerability superior levels of response and tolerability to haloperidol in the treatment of an acute to haloperidol in the treatment of an acute manic episode for up to12 weeks. manic episode for up to12 weeks.
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The goal of effective treatment in acute The goal of effective treatment in acute mania is to provide acute symptom mania is to provide acute symptom improvement and continued efficacy and improvement and continued efficacy and safety of treatment in the long term. safety of treatment in the long term. Despite effective treatment options, adherDespite effective treatment options, adherence to therapeutic regimens remains poor ence to therapeutic regimens remains poor in patients with bipolar disorder, with in patients with bipolar disorder, with studies reporting partial or total nonstudies reporting partial or total nonadherence rates of 40-60% (Colom & adherence rates of 40-60% (Colom & Vieta, 2002) . Aripiprazole is a novel Vieta, 2002) . Aripiprazole is a novel psychotropic agent with a distinctly differpsychotropic agent with a distinctly different mechanism of action from currently ent mechanism of action from currently available antipsychotics. It has been shown available antipsychotics. It has been shown to be effective for acute and long-term to be effective for acute and long-term treatment of schizophrenia and the treattreatment of schizophrenia and the treatment of acute mania, and is associated with ment of acute mania, and is associated with minimal potential for extrapyramidal minimal potential for extrapyramidal symptoms, weight gain and hyperprosymptoms, weight gain and hyperprolactinaemia (Kasper lactinaemia (Kasper et al et al, 2003; Keck , 2003; Keck et et al al, 2003; Marder , 2003; Marder et al et al, 2003; Pigott , 2003; Pigott et al et al, , 2003) . This 12-week study compared the 2003). This 12-week study compared the effectiveness of aripiprazole with haloeffectiveness of aripiprazole with haloperidol for treatment of an acute manic or peridol for treatment of an acute manic or mixed episode, based on patients remaining mixed episode, based on patients remaining on treatment and in response at week 12. on treatment and in response at week 12.
METHOD METHOD

Patient selection Patient selection
Patients eligible for enrolment in the study Patients eligible for enrolment in the study were men and women aged 18-65 years, were men and women aged 18-65 years, with a DSM-IV diagnosis of bipolar I diswith a DSM-IV diagnosis of bipolar I disorder (American Psychiatric Association, order (American Psychiatric Association, 1994) , receiving in-patient or out-patient 1994), receiving in-patient or out-patient treatment for an acute manic or mixed epitreatment for an acute manic or mixed episode. All patients were required to have a sode. All patients were required to have a Young Mania Rating Scale (YMRS; Young Young Mania Rating Scale (YMRS; Young et al et al, 1978 ) baseline score of 20 or above.
, 1978) baseline score of 20 or above. Exclusion criteria were the presence of Exclusion criteria were the presence of rapid-cycling bipolar I disorder; duration rapid-cycling bipolar I disorder; duration of the current manic episode of more than of the current manic episode of more than 4 weeks; proven substance misuse; patient 4 weeks; proven substance misuse; patient considered unresponsive to antipsychotics; considered unresponsive to antipsychotics; patient at significant risk of suicide; recent patient at significant risk of suicide; recent treatment with a long-acting antipsychotic, treatment with a long-acting antipsychotic, lithium or divalproate; use of psychotropic lithium or divalproate; use of psychotropic medications (other than benzodiazepines) medications (other than benzodiazepines) within 1 day of randomisation; fluoxetine within 1 day of randomisation; fluoxetine treatment in the past 4 weeks; and previous treatment in the past 4 weeks; and previous enrolment in an aripiprazole clinical study. enrolment in an aripiprazole clinical study.
Written informed consent was obtained Written informed consent was obtained from the patient or a legally acceptable from the patient or a legally acceptable representative. The study protocol, procerepresentative. The study protocol, procedures and consent statement were approved dures and consent statement were approved by the institutional review boards of all by the institutional review boards of all participating sites. participating sites.
Study design Study design
In this 12-week, multicentre, double-blind In this 12-week, multicentre, double-blind comparative trial, patients were randomcomparative trial, patients were randomised to receive either aripiprazole or haloised to receive either aripiprazole or haloperidol, using a fixed randomisation peridol, using a fixed randomisation schedule allocating patients between the schedule allocating patients between the two treatment arms in a 1:1 ratio. two treatment arms in a 1:1 ratio.
Phase 1 (weeks 1^3) Phase 1 (weeks 1^3)
Following a wash-out period of 1-3 days, Following a wash-out period of 1-3 days, patients fulfilling the entry criteria were patients fulfilling the entry criteria were randomised to receive aripiprazole 15 mg randomised to receive aripiprazole 15 mg per day or haloperidol 10 mg per day. At per day or haloperidol 10 mg per day. At the end of week 1 or 2, patients showing the end of week 1 or 2, patients showing a poor response to therapy, measured using a poor response to therapy, measured using the Clinical Global Impression (Spearing the Clinical Global Impression (Spearing et al et al, 1997) and defined as a Clinical Global , 1997) and defined as a Clinical Global Impression -Bipolar Disorder (CGI-BP) Impression -Bipolar Disorder (CGI-BP) Improvement (mania) score of 3 or above, Improvement (mania) score of 3 or above, could have their daily dosage increased to could have their daily dosage increased to aripiprazole 30 mg or haloperidol 15 mg. aripiprazole 30 mg or haloperidol 15 mg. Patients intolerant of the higher dosage Patients intolerant of the higher dosage could return to the initial lower dosage. could return to the initial lower dosage. Patients unable to tolerate 15 mg aripipraPatients unable to tolerate 15 mg aripiprazole or 10 mg haloperidol discontinued the zole or 10 mg haloperidol discontinued the trial. trial.
At the end of this 3-week period, At the end of this 3-week period, patients with a CGI-BP Severity (mania) patients with a CGI-BP Severity (mania) score of 4 or more (moderately ill or worse) score of 4 or more (moderately ill or worse) or a Montgomery-Asberg Depression Rator a Montgomery-Å sberg Depression Rating Scale (MADRS; Montgomery-Asberg, ing Scale (MADRS; Montgomery-Å sberg, 1979) score of 18 or more discontinued 1979) score of 18 or more discontinued the trial. the trial.
Phase 2 (weeks 4^12) Phase 2 (weeks 4^12)
Patients remaining in the study throughout Patients remaining in the study throughout weeks 4-12 continued with the treatment weeks 4-12 continued with the treatment and dose regimen prescribed in week 3. and dose regimen prescribed in week 3. The dosage of study medication could be The dosage of study medication could be decreased from 30 mg to 15 mg per day decreased from 30 mg to 15 mg per day for aripiprazole and from 15 mg to 10 mg for aripiprazole and from 15 mg to 10 mg per day for haloperidol if necessary for tolper day for haloperidol if necessary for tolerability, but not increased. If this lower erability, but not increased. If this lower dosage was not tolerated, the patient was dosage was not tolerated, the patient was withdrawn from the study. withdrawn from the study.
Patients were also withdrawn if there Patients were also withdrawn if there was a lack of maintained effect (originally was a lack of maintained effect (originally observed at week 3), or intolerance as observed at week 3), or intolerance as 2 3 5 2 3 5 
B R I T I S H J O UR N A L O F P SYC HI AT RY B R I T I S H J O UR N A L O F P S YC H I AT RY
( 2 0 0 5 ) , 1 8 7, 2 3 5^2 4 2 ( 2 0 0 5 ) , 1 8 7, 2 3 5^2 4
Efficacy assessments Efficacy assessments
The primary efficacy outcome was an effecThe primary efficacy outcome was an effectiveness measure of response. Responders tiveness measure of response. Responders were defined as patients who remained in were defined as patients who remained in therapy at week 12 and had a 50% or therapy at week 12 and had a 50% or greater improvement from baseline in greater improvement from baseline in YMRS total score. Assessments (YMRS, YMRS total score. Assessments (YMRS, CGI-BP and MADRS) were made at base-CGI-BP and MADRS) were made at baseline, days 4, 7, 10 and 14, then weekly until line, days 4, 7, 10 and 14, then weekly until week 6 and every 2 weeks during weeks week 6 and every 2 weeks during weeks 6-12. 6-12. Secondary efficacy measures included Secondary efficacy measures included the response rate at week 3 (i.e. remaining the response rate at week 3 (i.e. remaining in treatment with a 50% or greater in treatment with a 50% or greater improvement in YMRS total score from improvement in YMRS total score from baseline) and time to discontinuation for baseline) and time to discontinuation for any reason. any reason.
Safety and tolerability assessments Safety and tolerability assessments
Adverse event reports were gathered Adverse event reports were gathered throughout the study and evaluated by throughout the study and evaluated by investigators for severity and likely investigators for severity and likely relationship to study medication. Extrarelationship to study medication. Extrapyramidal symptoms were evaluated using pyramidal symptoms were evaluated using the Simpson-Angus Scale (SAS; Simpson the Simpson-Angus Scale (SAS; Simpson & Angus, 1970) , the Barnes Akathisia Scale & Angus, 1970), the Barnes Akathisia Scale (BAS; Barnes, 1989) and the Abnormal (BAS; Barnes, 1989) Health, 1975) , administered at baseline and at 1975), administered at baseline and at weeks 1 (except for AIMS), 2, 3, 6 and 12. weeks 1 (except for AIMS), 2, 3, 6 and 12.
Patients' vital signs were measured at Patients' vital signs were measured at screening and each assessment visit during screening and each assessment visit during the study. Electrocardiograms, serum prothe study. Electrocardiograms, serum prolactin concentrations, routine laboratory lactin concentrations, routine laboratory tests, body weight measurements and physitests, body weight measurements and physical examinations were performed at screencal examinations were performed at screening and at weeks 3, 8 (except physical ing and at weeks 3, 8 (except physical examinations) and 12. examinations) and 12.
Concomitant medications Concomitant medications
The following medications were prohibited The following medications were prohibited during the study: antipsychotic agents, during the study: antipsychotic agents, mood stabilisers/anti-epileptics, lithium, mood stabilisers/anti-epileptics, lithium, benzodiazepines (except lorazepam 4 mg benzodiazepines (except lorazepam 4 mg per day or oxazepam 60 mg per day during per day or oxazepam 60 mg per day during days 1-4, and lorazepam 2 mg per day or days 1-4, and lorazepam 2 mg per day or oxazepam 30 mg per day during days oxazepam 30 mg per day during days 5-10), antidepressants and all other 5-10), antidepressants and all other psychotropic drugs. Anticholinergic agents psychotropic drugs. Anticholinergic agents were not permitted for symptomatic or were not permitted for symptomatic or prophylactic treatment of extrapyramidal prophylactic treatment of extrapyramidal symptoms during the study, because of symptoms during the study, because of their potential to mask differences in their potential to mask differences in treatment tolerability between the two treatment tolerability between the two agents. agents.
Statistical methods Statistical methods
The primary outcome measure (number of The primary outcome measure (number of patients on treatment and in response at patients on treatment and in response at week 12) was evaluated by the Cochranweek 12) was evaluated by the CochranMantel-Haenszel test (unstratified) using Mantel-Haenszel test (unstratified) using the safety sample (patients randomised to the safety sample (patients randomised to treatment and who took at least one dose treatment and who took at least one dose of study medication). Patients of study medication). Patients who disconwho discontinued the study during the tinued the study during the 12-week phase 12-week phase and patients without a 50% or greater imand patients without a 50% or greater improvement in YMRS total score at week provement in YMRS total score at week 12 were considered to be non-responders. 12 were considered to be non-responders. Response rates at week 3 were also evaluResponse rates at week 3 were also evaluated using the Cochran-Mantel-Haenszel ated using the Cochran-Mantel-Haenszel test. Change from baseline measures were test. Change from baseline measures were evaluated by analysis of covariance (ANevaluated by analysis of covariance (AN-COVA) with treatment as main effect and COVA) with treatment as main effect and baseline value as covariate. All efficacy baseline value as covariate. All efficacy analyses were performed on the last analyses were performed on the last observation carried forward (LOCF) and observation carried forward (LOCF) and observed cases data-sets. Time to discontiobserved cases data-sets. Time to discontinuation was evaluated using the log rank nuation was evaluated using the log rank test. test.
RESULTS RESULTS
Patient characteristics Patient characteristics
The study was conducted at 76 interThe study was conducted at 76 international centres. A total of 347 patients national centres. A total of 347 patients were randomised to medication (aripiprawere randomised to medication (aripiprazole, zole, n n¼175; haloperidol, 175; haloperidol, n n¼172). Of 172). Of those, 344 received at least one dose of those, 344 received at least one dose of study medication (safety sample); 338 study medication (safety sample); 338 patients received study medication and patients received study medication and had at least one post-baseline efficacy had at least one post-baseline efficacy rating (efficacy sample). The progress of rating (efficacy sample). The progress of participants through the trial is illustrated participants through the trial is illustrated in Fig. 1 . Most randomised patients were in Fig. 1 . Most randomised patients were 2 3 6 2 3 6 female (62%) and the majority of patients female (62%) and the majority of patients presented with a manic index episode presented with a manic index episode (89%). Mean baseline YMRS and CGI-BP (89%). Mean baseline YMRS and CGI-BP Severity (mania) scores were similar in the Severity (mania) scores were similar in the two treatment arms (Table 1) . At week 3, two treatment arms (Table 1) . At week 3, the average daily dosage of aripiprazole the average daily dosage of aripiprazole was 22.6 mg and of haloperidol was was 22.6 mg and of haloperidol was 11.6 mg. At week 12, average daily dosages 11.6 mg. At week 12, average daily dosages were 21.6 mg for aripiprazole and 11.1 mg were 21.6 mg for aripiprazole and 11.1 mg for haloperidol. for haloperidol. . At the end of the second CI 11.4-30.9). At the end of the second phase, 89 (50.9%) and 50 (29.1%) patients phase, 89 (50.9%) and 50 (29.1%) patients had completed 12 weeks of aripiprazole or had completed 12 weeks of aripiprazole or haloperidol treatment, respectively haloperidol treatment, respectively ( (P P5 50.001; difference 21.8%, 95% CI 0.001; difference 21.8%, 95% CI 11.4-31.7). 11.4-31.7).
Patient disposition Patient disposition
Efficacy Efficacy
At week 12, aripiprazole showed signifiAt week 12, aripiprazole showed significantly greater response rates compared cantly greater response rates compared with haloperidol ( Fig. 2) . In the aripiprawith haloperidol ( Fig. 2 ). In the aripiprazole group, 49.7% of patients continued zole group, 49.7% of patients continued to respond to therapy, whereas the response to respond to therapy, whereas the response rate in the haloperidol arm was 28.4% rate in the haloperidol arm was 28.4% ( (P P5 50.001). Both aripiprazole and haloper-0.001). Both aripiprazole and haloperidol treatment produced marked improveidol treatment produced marked improvements in mean YMRS total scores from ments in mean YMRS total scores from baseline ( Fig. 3) . At week 12, YMRS total baseline ( Fig. 3) . At week 12, YMRS total scores showed mean reductions of 19.9 scores showed mean reductions of 19.9 with aripiprazole and 18.2 with haloperidol with aripiprazole and 18.2 with haloperidol from baseline (LOCF analysis; from baseline (LOCF analysis; P P¼0.226). 0.226). Among patients remaining in therapy, Among patients remaining in therapy, aripiprazole produced a significantly greataripiprazole produced a significantly greater mean reduction in YMRS total score at er mean reduction in YMRS total score at week 12 than haloperidol ( week 12 than haloperidol (7 729.0 29.0 v. v. 7 727.4; 27.4; P P¼0.044). The proportion of 0.044). The proportion of patients in remission (YMRS total score patients in remission (YMRS total score 5 512) at week 12 was significantly higher 12) at week 12 was significantly higher in the aripiprazole group than in the haloin the aripiprazole group than in the haloperidol group (50% peridol group (50% v.
v. 27%; 27%; P P5 50.001). 0.001). Treatment with aripiprazole and haloTreatment with aripiprazole and haloperidol was associated with marked mean peridol was associated with marked mean reductions in CGI-BP Severity (mania) reductions in CGI-BP Severity (mania) scores (Fig. 4) . Over the 12-week study, scores (Fig. 4) . Over the 12-week study, aripiprazole and haloperidol reduced aripiprazole and haloperidol reduced CGI-BP Severity (mania) scores by 2.58 CGI-BP Severity (mania) scores by 2.58 and 2.27 points, respectively (LOCF analyand 2.27 points, respectively (LOCF analysis; sis; P P¼0.095). Mean decreases in CGI-BP 0.095). Mean decreases in CGI-BP Severity (mania) scores were also similar Severity (mania) scores were also similar in the two groups using observed cases in the two groups using observed cases analysis (aripiprazole analysis (aripiprazole 7 73.71, haloperidol 3.71, haloperidol 7 73.55). Other efficacy measures showed 3.55). Other efficacy measures showed similar changes in the aripiprazole and similar changes in the aripiprazole and haloperidol groups with both LOCF and haloperidol groups with both LOCF and observed cases analyses (Table 2) . observed cases analyses (Table 2) .
At week 3 of the first phase, 50.9% of At week 3 of the first phase, 50.9% of aripiprazole-treated patients responded to aripiprazole-treated patients responded to treatment compared with 42.6% of treatment compared with 42.6% of haloperidol-treated patients ( haloperidol-treated patients (P P¼0.126; 0.126; RR RR¼1.19, 95% CI 0.95-1.50) (see Fig. 2 ).
1.19, 95% CI 0.95-1.50) (see Fig. 2 ). An initial rapid reduction in YMRS was An initial rapid reduction in YMRS was noted in the first 3 weeks of therapy noted in the first 3 weeks of therapy (aripiprazole (aripiprazole 7 715.7, haloperidol 15.7, haloperidol 7 715.7; 15.7; LOCF), with responses sustained and LOCF), with responses sustained and 2 3 7 2 3 7 (*** (***P P5 50.001 0.001v. v. haloperidol). haloperidol). (92) 161 (92) 148 (86) 148 (86) 309 (89) 309 (89) Mixed Mixed 14 (8) 14 (8) 24 (14) 24 (14) 38 (11) improving over subsequent weeks of treatimproving over subsequent weeks of treatment. Marked reductions in CGI-BP ment. Marked reductions in CGI-BP Severity scores for mania (aripiprazole Severity scores for mania (aripiprazole 7 72.0, haloperidol 2.0, haloperidol 7 71.9; LOCF) and over-1.9; LOCF) and overall bipolar illness (aripiprazole all bipolar illness (aripiprazole 7 71.6, halo-1.6, haloperidol peridol 7 71.4; LOCF) were also observed at 1.4; LOCF) were also observed at week 3 with both treatments, whereas week 3 with both treatments, whereas CGI-BP depression scores showed minimal CGI-BP depression scores showed minimal change from baseline in either group (aripichange from baseline in either group (aripiprazole 0.0, haloperidol 0.1; LOCF). The prazole 0.0, haloperidol 0.1; LOCF). The proportion of patients in remission (YMRS proportion of patients in remission (YMRS total score total score 5 512) was 35% with aripipra-12) was 35% with aripiprazole and 31% with haloperidol treatment zole and 31% with haloperidol treatment at week 3. Differences between the groups at week 3. Differences between the groups were not statistically significant for any of were not statistically significant for any of these assessments. these assessments.
Depression ratings Depression ratings
Mean baseline MADRS total scores were Mean baseline MADRS total scores were similar in both treatment groups (aripiprasimilar in both treatment groups (aripiprazole 9.24, haloperidol 9.75; LOCF). Signifzole 9.24, haloperidol 9.75; LOCF). Significantly more patients demonstrated a 50% icantly more patients demonstrated a 50% or greater decrease in MADRS total score or greater decrease in MADRS total score from baseline with aripiprazole than with from baseline with aripiprazole than with haloperidol at week 3 (51% haloperidol at week 3 (51% v.
v. 37%; 37%; P P¼0.007) and week 12 (51% 0.007) and week 12 (51% v. v. 33%; 33%; P P¼0.001). Aripiprazole treatment pro-0.001). Aripiprazole treatment produced significantly greater reductions in duced significantly greater reductions in depressive symptoms compared with halodepressive symptoms compared with haloperidol, as measured by the mean change peridol, as measured by the mean change in MADRS total score at week 3 (aripiprain MADRS total score at week 3 (aripiprazole zole 7
73.1, haloperidol 3.1, haloperidol 7 71.6; 1.6; P P¼0.027; 0.027; LOCF) (Fig. 5) . Statistically significant LOCF) (Fig. 5) . Statistically significant ( (P P5 50.05) differences between the groups 0.05) differences between the groups were observed at weeks 3 through 6, and were observed at weeks 3 through 6, and the week 8 results approached significance the week 8 results approached significance ( (P P¼0.051). Improvements in depressive 0.051). Improvements in depressive symptoms with aripiprazole were sustained symptoms with aripiprazole were sustained at week 12, but did not reach significance at week 12, but did not reach significance compared with haloperidol (aripiprazole compared with haloperidol (aripiprazole 7 72.0, haloperidol 2.0, haloperidol 7 70.7; 0.7; P P¼0.150; LOCF). 0.150; LOCF). Patients experiencing a switch to dePatients experiencing a switch to depression were defined pression were defined post hoc post hoc as those as those whose CGI-BP depression sub-scale scores whose CGI-BP depression sub-scale scores worsened by worsened by 5 52 points (CGI-BP depres-2 points (CGI-BP depression scores were available for 337 of the sion scores were available for 337 of the participants 
Safety Safety
Adverse events Adverse events
The most frequently reported adverse The most frequently reported adverse events during the study are shown in Table  events during the study are shown in Table  3 . The most frequent adverse events leading 3. The most frequent adverse events leading to discontinuation ( to discontinuation (5 510% in at least one of 10% in at least one of the two treatment arms) were extrathe two treatment arms) were extrapyramidal symptoms (haloperidol, pyramidal symptoms (haloperidol, n n¼32 32 (18.9%); aripiprazole, (18.9%); aripiprazole, n n¼5 (2.9%)), and 5 (2.9%)), and akathisia (haloperidol, akathisia (haloperidol, n n¼24 (14.2%); 24 (14.2%); aripiprazole, aripiprazole, n n¼9 (5.1%)). Overall, 18 9 (5.1%)). Overall, 18 patients had a serious adverse event during patients had a serious adverse event during the study or within 30 days of discontinthe study or within 30 days of discontinuation (aripiprazole, uation (aripiprazole, n n¼6; haloperidol, 6; haloperidol, n n¼12). In general these were related to 12). In general these were related to the underlying diagnosis. One patient in the underlying diagnosis. One patient in the haloperidol group discontinued the haloperidol group discontinued treatment because of liver damage considtreatment because of liver damage considered possibly related to study medication. ered possibly related to study medication.
Patient discontinuations Patient discontinuations
Overall, 208 patients (59.9%) discontinued Overall, 208 patients (59.9%) discontinued treatment during the 12-week study: halotreatment during the 12-week study: haloperidol, peridol, n n¼122 (70.9%); aripiprazole, 122 (70.9%); aripiprazole, 2 3 8 2 3 8 n n¼86 (49.1%). During the study, time to 86 (49.1%). During the study, time to discontinuation for any reason was signifidiscontinuation for any reason was significantly greater for patients receiving aripicantly greater for patients receiving aripiprazole than those receiving haloperidol prazole than those receiving haloperidol ( (P P5 50.001) (Fig. 6) . The hazard ratio for 0.001) (Fig. 6 ). The hazard ratio for discontinuation of haloperidol over discontinuation of haloperidol over aripiprazole was 1.96 (95% CI 1.48-aripiprazole was 1.96 (95% CI 1.48-2.59). In addition, 13 patients (aripipra-2.59). In addition, 13 patients (aripiprazole, zole, n n¼5; haloperidol, 5; haloperidol, n n¼8) who com-8) who completed the first 3 weeks of treatment did pleted the first 3 weeks of treatment did not enter the second phase of the study not enter the second phase of the study (weeks 4-12). (weeks 4-12).
In weeks 1-3 of the study, 118 patients In weeks 1-3 of the study, 118 patients (34.0%) discontinued treatment: haloperi-(34.0%) discontinued treatment: haloperidol, dol, n n¼77 (44.8%); aripiprazole, 77 (44.8%); aripiprazole, n n¼41 41 (23.4%). The most common reason for dis-(23.4%). The most common reason for discontinuation was experiencing adverse continuation was experiencing adverse events (20.2%), which showed a marked events (20.2%), which showed a marked difference in incidence between the groups difference in incidence between the groups (aripiprazole, 9.7%; haloperidol, 30.8%). (aripiprazole, 9.7%; haloperidol, 30.8%). Other reasons for discontinuation included Other reasons for discontinuation included patient withdrawal of consent (6.1%) and patient withdrawal of consent (6.1%) and lack of efficacy (5.2%). In weeks 4-12 of lack of efficacy (5.2%). In weeks 4-12 of the study, 77 patients (22.2%) discontinued the study, 77 patients (22.2%) discontinued treatment: haloperidol, treatment: haloperidol, n n¼37 (21.5%); ari-37 (21.5%); aripiprazole, piprazole, n n¼40 (22.9%). The most com-40 (22.9%). The most common reason for discontinuation was mon reason for discontinuation was experiencing adverse events (overall, experiencing adverse events (overall, 11.5%; aripiprazole, 8.6%; haloperidol, 11.5%; aripiprazole, 8.6%; haloperidol, 14.5%). Other reasons for discontinuation 14.5%). Other reasons for discontinuation were similar in incidence to those in weeks were similar in incidence to those in weeks 1-3. 1-3.
Extrapyramidal adverse events Extrapyramidal adverse events
The incidence of extrapyramidal adverse The incidence of extrapyramidal adverse events in the haloperidol group (62.7%) events in the haloperidol group (62.7%) was more than double that in the was more than double that in the aripiprazole group (24.0%). Extrapyramiaripiprazole group (24.0%). Extrapyramidal syndrome and akathisia were the most dal syndrome and akathisia were the most frequently reported of these adverse events, frequently reported of these adverse events, and were much more frequent with haloand were much more frequent with haloperidol than with aripiprazole (see Table  peridol than with aripiprazole (see Table  3 ). The SAS, BAS and AIMS scores all 3). The SAS, BAS and AIMS scores all showed minimal changes from baseline to showed minimal changes from baseline to end-point with aripiprazole. Significantly end-point with aripiprazole. Significantly greater mean increases (i.e. worsening) in greater mean increases (i.e. worsening) in scores were observed with haloperidol comscores were observed with haloperidol compared with aripiprazole ( pared with aripiprazole (P P4 40.002) (Fig. 6) . 0.002) (Fig. 6 ). Rating scale scores at week 3 also showed Rating scale scores at week 3 also showed minimal mean changes from baseline with minimal mean changes from baseline with aripiprazole treatment, and larger mean aripiprazole treatment, and larger mean increases with haloperidol treatment increases with haloperidol treatment ( 
Body weight Body weight
The mean change in weight from baseline The mean change in weight from baseline at week 12 (LOCF) was not significantly at week 12 (LOCF) was not significantly different between the aripiprazole different between the aripiprazole (+0.27 kg) and haloperidol ( (+0.27 kg) and haloperidol (7 70.10 kg) 0.10 kg) groups. Small mean changes in weight were groups. Small mean changes in weight were also observed from baseline to week 3 also observed from baseline to week 3 (observed cases) with both aripiprazole (observed cases) with both aripiprazole ( (7 70.08 kg) and haloperidol (+0.28 kg). 
Serum prolactin levels Serum prolactin levels
Serum prolactin levels showed a mean Serum prolactin levels showed a mean decrease from baseline in the aripiprazole decrease from baseline in the aripiprazole group ( group (7 713.4 ng/ml, 13.4 ng/ml, 7 7284.1 mU/l), and a 284.1 mU/l), and a mean increase in the haloperidol group mean increase in the haloperidol group (7.7 ng/ml, (7.7 ng/ml, 7 7163.2 mU/l) at week 12; this 163.2 mU/l) at week 12; this difference was statistically significant difference was statistically significant ( (P P5 50.001). Similar changes in prolactin 0.001). Similar changes in prolactin levels were observed at week 3 (aripipralevels were observed at week 3 (aripiprazole zole 7 712.5 ng/ml ( 12.5 ng/ml (7 7265 mU/l), halo-265 mU/l), haloperidol 15.5 ng/ml (328.6 mU/l); observed peridol 15.5 ng/ml (328.6 mU/l); observed cases analysis). In the haloperidol group, cases analysis). In the haloperidol group, 57.1% of patients experienced serum 57.1% of patients experienced serum prolactin levels above the upper limit of prolactin levels above the upper limit of 2 3 9 2 3 9 together with hazard ratio evaluation (unstratified log rank, together with hazard ratio evaluation (unstratified log rank, P P5 50.001). 0.001).
normal compared with 14.1% in the normal compared with 14.1% in the aripiprazole group. aripiprazole group.
Electrocardiography Electrocardiography
Electrocardiogram (ECG) analysis showed Electrocardiogram (ECG) analysis showed an on-treatment QT an on-treatment QT c c value of 450 ms or value of 450 ms or more and a 10% or greater increase from more and a 10% or greater increase from baseline for 4 patients (2.7%) in the halobaseline for 4 patients (2.7%) in the haloperidol group and 5 patients (3.0%) in the peridol group and 5 patients (3.0%) in the aripiprazole group, calculated using aripiprazole group, calculated using Bazett's (1920) formula, and no patient in Bazett's (1920) formula, and no patient in either group using the Food and Drug either group using the Food and Drug Administration (2000) NeuropharmacoloAdministration (2000) Neuropharmacological Division formula. There was no disgical Division formula. There was no discontinuation owing to ECG abnormalities. continuation owing to ECG abnormalities.
Vital signs and laboratory analyses Vital signs and laboratory analyses
No clinically meaningful difference was No clinically meaningful difference was detected in vital sign measurements, laboradetected in vital sign measurements, laboratory abnormalities or cholesterol levels tory abnormalities or cholesterol levels between the aripiprazole and haloperidol between the aripiprazole and haloperidol treatment groups. treatment groups.
DISCUSSION DISCUSSION
The results of this study demonstrate that The results of this study demonstrate that aripiprazole offers superior effectiveness to aripiprazole offers superior effectiveness to haloperidol in the treatment of patients haloperidol in the treatment of patients with acute mania for up to 12 weeks. with acute mania for up to 12 weeks. Aripiprazole demonstrated similar efficacy, Aripiprazole demonstrated similar efficacy, together with improved sustained together with improved sustained response rates and tolerability, compared response rates and tolerability, compared with haloperidol, indicative of improved with haloperidol, indicative of improved effectiveness. effectiveness.
Haloperidol was chosen as an active Haloperidol was chosen as an active comparator in this study because of the comparator in this study because of the extensive study of this drug as an effective extensive study of this drug as an effective treatment of the manic symptoms, includtreatment of the manic symptoms, including psychosis, of acute mania (Garfinkel ing psychosis, of acute mania (Garfinkel et et al al, 1980) . Several atypical antipsychotic , 1980) . Several atypical antipsychotic studies examining treatment of acute mania studies examining treatment of acute mania in patients with bipolar disorder have used in patients with bipolar disorder have used haloperidol as an active control (Segal haloperidol as an active control (Segal et al et al, , 1998; Tohen 1998; Tohen et al et al, 2003; McIntyre , 2003; McIntyre et al et al, , 2005; Smulevich 2005; Smulevich et al et al, 2005) . In these , 2005). In these studies, haloperidol-treated patients showed studies, haloperidol-treated patients showed similar improvements in mania rating scale similar improvements in mania rating scale scores to those receiving atypical (olanzascores to those receiving atypical (olanzapine or risperidone) therapy (Segal pine or risperidone) therapy (Segal et al et al, , 1998; Tohen 1998; Tohen et al et al, 2003) , and remission , 2003), and remission rates were similar at week 6 and week 12 rates were similar at week 6 and week 12 with olanzapine and haloperidol in the with olanzapine and haloperidol in the comparison study (Tohen comparison study (Tohen et al et al, 2003) . , 2003).
Treatment effectiveness Treatment effectiveness
The primary outcome measure in our study The primary outcome measure in our study showed that a significantly greater number showed that a significantly greater number of aripiprazole-treated patients continued of aripiprazole-treated patients continued to respond to treatment at week 12, as to respond to treatment at week 12, as measured by a 50% or greater improvemeasured by a 50% or greater improvement in YMRS total score from baseline ment in YMRS total score from baseline and remaining in therapy, compared with and remaining in therapy, compared with patients treated with haloperidol (49.7% patients treated with haloperidol (49.7% v. v. 28.4%, 28.4%, P P5 50.001). This outcome mea-0.001). This outcome measure is affected by both efficacy and tolersure is affected by both efficacy and tolerability, and was chosen to reflect the ability, and was chosen to reflect the combination of efficacy, safety and tolercombination of efficacy, safety and tolerability required for a treatment to be effecability required for a treatment to be effective in clinical practice. tive in clinical practice.
Analysis of YMRS and CGI measures Analysis of YMRS and CGI measures showed similar efficacy improvements with showed similar efficacy improvements with both aripiprazole and haloperidol treatboth aripiprazole and haloperidol treatment. Total YMRS scores showed marked ment. Total YMRS scores showed marked improvements with both aripiprazole and improvements with both aripiprazole and haloperidol, which were sustained over haloperidol, which were sustained over the 12-week study. Both treatments prothe 12-week study. Both treatments provided rapid control of manic symptoms, vided rapid control of manic symptoms, with marked decreases in YMRS scores with marked decreases in YMRS scores from baseline observed with aripiprazole from baseline observed with aripiprazole and haloperidol at week 3. The improveand haloperidol at week 3. The improvements in YMRS scores seen with aripipraments in YMRS scores seen with aripiprazole therapy in our study are comparable zole therapy in our study are comparable with those observed in 12-week compariwith those observed in 12-week comparison studies of haloperidol with olanzapine son studies of haloperidol with olanzapine (Tohen (Tohen et al v. haloperhaloperidol study (Segal idol study (Segal et al et al, 1998) . , 1998). The similar improvements in efficacy The similar improvements in efficacy scores observed with aripiprazole and haloscores observed with aripiprazole and haloperidol treatment in this study are consisperidol treatment in this study are consistent with findings from comparison tent with findings from comparison studies with olanzapine (Tohen studies with olanzapine (Tohen et al et al, , 2003) and risperidone (Segal 2003) and risperidone (Segal et al et al, 1998 (Segal et al et al, ), , 1998 , which also showed similar improvements which also showed similar improvements with haloperidol and atypical therapy. with haloperidol and atypical therapy. The difference between the efficacy and The difference between the efficacy and effectiveness results observed in our study effectiveness results observed in our study highlights the impact that tolerability has highlights the impact that tolerability has on overall treatment effectiveness. The on overall treatment effectiveness. The superior maintained response observed superior maintained response observed with aripiprazole at week 12 reflects the inwith aripiprazole at week 12 reflects the increased ability of patients to continue creased ability of patients to continue taking aripiprazole compared with halotaking aripiprazole compared with haloperidol, which is a pragmatic outcome peridol, which is a pragmatic outcome measure with high external validity. measure with high external validity.
Depressive symptoms Depressive symptoms
It has been suggested that the use of typical It has been suggested that the use of typical antipsychotic therapy might worsen or inantipsychotic therapy might worsen or induce depression in this patient population duce depression in this patient population (Vieta, 2003) . In this study, fewer patients (Vieta, 2003) . In this study, fewer patients receiving aripiprazole experienced a switch receiving aripiprazole experienced a switch to depression compared with those receivto depression compared with those receiving haloperidol (11.0% ing haloperidol (11.0% v.
v. 17.7%), 17.7%), although this did not reach statistical signifalthough this did not reach statistical significance. Similar findings have been reported icance. Similar findings have been reported in studies with olanzapine and quetiapine in studies with olanzapine and quetiapine (Brecher & Huizar, 2003; Tohen (Brecher & Huizar, 2003; Tohen et al et al, , 2003) , suggesting that atypical antipsycho-2003), suggesting that atypical antipsychotics may offer benefits over typical agents tics may offer benefits over typical agents in preventing or delaying the switch to dein preventing or delaying the switch to depression in patients with bipolar disorder. pression in patients with bipolar disorder.
Aripiprazole was associated with signifAripiprazole was associated with significant improvements in depressive sympicant improvements in depressive symptoms over the course of the study. toms over the course of the study. Significantly more patients demonstrated a Significantly more patients demonstrated a 50% or greater decrease in MADRS total 50% or greater decrease in MADRS total score from baseline with aripiprazole than score from baseline with aripiprazole than with haloperidol at week 3 and week 12. with haloperidol at week 3 and week 12. Reductions in MADRS total scores from Reductions in MADRS total scores from baseline occurred rapidly after the start of baseline occurred rapidly after the start of aripiprazole therapy, with significant differaripiprazole therapy, with significant differences from haloperidol observed at week 3, ences from haloperidol observed at week 3, although statistical significance was not although statistical significance was not maintained at week 12. maintained at week 12.
Treatment adherence Treatment adherence
Full adherence to treatment is associated Full adherence to treatment is associated with improved long-term patient outcome with improved long-term patient outcome (Tsai (Tsai et al & Rush, 2003) . Treatment safety and tolerability are, therefore, key factors in patient ability are, therefore, key factors in patient outcome. In this study, the time to discontioutcome. In this study, the time to discontinuation for any reason was significantly nuation for any reason was significantly greater for patients receiving aripiprazole greater for patients receiving aripiprazole than for those treated with haloperidol than for those treated with haloperidol ( (P P5 50.001). Hazard ratio calculations sug-0.001). Hazard ratio calculations suggest that patients given haloperidol were gest that patients given haloperidol were almost twice as likely to discontinue almost twice as likely to discontinue therapy as those given aripiprazole therapy as those given aripiprazole ( (P P5 50.001), adverse events being the most 0.001), adverse events being the most frequent reason for discontinuation. frequent reason for discontinuation.
Adverse events Adverse events
Extrapyramidal syndrome, akathisia and Extrapyramidal syndrome, akathisia and tremor are common in patients receiving tremor are common in patients receiving typical antipsychotic agents. In this study, typical antipsychotic agents. In this study, patients taking haloperidol reported a patients taking haloperidol reported a four-fold increased incidence of extrafour-fold increased incidence of extrapyramidal symptoms compared with pyramidal symptoms compared with patients taking aripiprazole (36% patients taking aripiprazole (36% v.
v. 9%). 9% , 2003) . This, and the lack of hyperprolacti-2003). This, and the lack of hyperprolactinaemia observed with aripiprazole in this naemia observed with aripiprazole in this study, may be explained by this drug's study, may be explained by this drug's unique mode of action as a dopamine D unique mode of action as a dopamine D 2 2 partial agonist (Lieberman, 2004) ; these partial agonist (Lieberman, 2004) ; these agonists act as functional antagonists in agonists act as functional antagonists in areas of high dopamine concentrations but areas of high dopamine concentrations but not in areas of normal dopamine levels, not in areas of normal dopamine levels, such as the nigrostriatal and tubero-infunsuch as the nigrostriatal and tubero-infundibular pathways, thus reducing symptoms dibular pathways, thus reducing symptoms without producing movement disorders or without producing movement disorders or elevated prolactin levels. In regions of low elevated prolactin levels. In regions of low dopamine concentration, a D dopamine concentration, a D 2 2 partial partial agonist will show functional agonist agonist will show functional agonist activity. activity.
Minimal mean changes in body weight Minimal mean changes in body weight were observed with both aripiprazole and were observed with both aripiprazole and haloperidol over the 12-week study. Lack haloperidol over the 12-week study. Lack of weight gain is an important treatment of weight gain is an important treatment consideration, given the adverse effects of consideration, given the adverse effects of weight gain on treatment adherence and weight gain on treatment adherence and its implications for long-term patient its implications for long-term patient health. Weight gain and obesity are estabhealth. Weight gain and obesity are established risk factors for cardiovascular dislished risk factors for cardiovascular disease and diabetes, and are associated with ease and diabetes, and are associated with dyslipidaemia (National Institutes of dyslipidaemia (National Institutes of Health, 1998 
Study limitations Study limitations
The findings of this study should, however, The findings of this study should, however, be considered in the light of the following be considered in the light of the following limitations. The overall study completion limitations. The overall study completion rates could limit the generalisability of the rates could limit the generalisability of the results. The lack of anticholinergic mediresults. The lack of anticholinergic medication use specified by the study protocol cation use specified by the study protocol and the limited dose range permitted for and the limited dose range permitted for haloperidol could have affected the results haloperidol could have affected the results through a possible impact on the ability of through a possible impact on the ability of patients to tolerate haloperidol. It may also patients to tolerate haloperidol. It may also limit the extent to which the haloperidol limit the extent to which the haloperidol findings can be generalised to clinical pracfindings can be generalised to clinical practice. However, extrapyramidal symptom tice. However, extrapyramidal symptom rates with haloperidol were similar to those rates with haloperidol were similar to those reported in other 12-week studies that evalreported in other 12-week studies that evaluated lower doses of haloperidol and uated lower doses of haloperidol and permitted the use of anticholinergic permitted the use of anticholinergic medications to manage these symptoms medications to manage these symptoms (Tohen (Tohen et al et al, 2003; McIntyre , 2003; McIntyre et al et al, 2005; , 2005; Smulevich Smulevich et al et al, 2005) . The use of an atypi-, 2005). The use of an atypical antipsychotic as a comparator in future cal antipsychotic as a comparator in future studies would be expected to overcome the studies would be expected to overcome the tolerability limitations associated with hatolerability limitations associated with haloperidol, and reflect the increasingly wideloperidol, and reflect the increasingly widespread use of atypicals for the treatment of spread use of atypicals for the treatment of mania (Vieta, 2003) . mania (Vieta, 2003) . Significantly greater sustained response rates and tolerability observed with aripiprazole suggest it may offer a more effective treatment option than haloperidol. aripiprazole suggest it may offer a more effective treatment option than haloperidol.
LIMITATIONS LIMITATIONS
& & The overall study completion rates could limit the generalisability of the results.
The overall study completion rates could limit the generalisability of the results.
& & The protocol-specified lack of anticholinergic medication use and the limited The protocol-specified lack of anticholinergic medication use and the limited dosage range permitted for haloperidol could limit the applicability of haloperidol dosage range permitted for haloperidol could limit the applicability of haloperidol findings to clinical practice. findings to clinical practice.
& & Low tolerability, and hence a large attrition rate, limits the usefulness of Low tolerability, and hence a large attrition rate, limits the usefulness of haloperidol as comparator. haloperidol as comparator.
